Betta Pharmaceuticals Co., Ltd.

XSEC:300558 Stock Report

Market Cap: CN¥21.6b

Betta Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Betta Pharmaceuticals's earnings have been declining at an average annual rate of -3.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 10.8% per year. Betta Pharmaceuticals's return on equity is 7.8%, and it has net margins of 16.7%.

Key information

-3.4%

Earnings growth rate

-4.4%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate10.8%
Return on equity7.8%
Net Margin16.7%
Next Earnings Update18 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Betta Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300558 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,7574601,270556
30 Jun 242,6434241,185562
31 Mar 242,6603951,201618
31 Dec 232,4563481,121640
30 Sep 232,7573471,318686
30 Jun 232,4371991,145717
31 Mar 232,3241131,181768
31 Dec 222,3771451,236700
30 Sep 222,1841391,198682
30 Jun 222,3442631,308640
31 Mar 222,2123191,156555
01 Jan 222,2463831,141566
30 Sep 212,0874391,041462
30 Jun 212,0746781,026434
31 Mar 211,842624905392
31 Dec 201,870606947363
30 Sep 201,818546930348
30 Jun 201,744287898337
31 Mar 201,826310945349
31 Dec 191,554231820326
30 Sep 191,540218818362
30 Jun 191,405187771342
31 Mar 191,314176729316
31 Dec 181,224167672304
30 Sep 181,186202654242
30 Jun 181,110187513326
31 Mar 181,081225528257
31 Dec 171,026258525203
30 Sep 171,016264558147
30 Jun 171,0152946680
31 Mar 179903416010
31 Dec 161,0353696190
30 Sep 169873645790
31 Dec 159153455090
31 Dec 147042713790

Quality Earnings: 300558 has a large one-off gain of CN¥159.4M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300558's current net profit margins (16.7%) are higher than last year (12.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300558's earnings have declined by 3.4% per year over the past 5 years.

Accelerating Growth: 300558's earnings growth over the past year (32.3%) exceeds its 5-year average (-3.4% per year).

Earnings vs Industry: 300558 earnings growth over the past year (32.3%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 300558's Return on Equity (7.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 01:16
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Betta Pharmaceuticals Co., Ltd. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue GaoChangjiang Securities Co. LTD.
Jin ZhangChina International Capital Corporation Limited
Jing QiangChina International Capital Corporation Limited